Lubiprostone Capsule
Product Images NDC 72603-288

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lubiprostone (NDC 72603-288). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

24mcg-60s (24mcg 60s)

24mcg-60s (24mcg 60s)
Lubiprostone Capsules 24 mcg in a 60-capsule package label. The label indicates the product is for prescription use only and instructs to swallow capsules whole without breaking or chewing. Manufactured for Northstar Rx LLC by Ascent Pharmaceuticals, with storage instructions and a barcode present.*
FDA Label Image

8mcg-60s (8mcg 60s)

8mcg-60s (8mcg 60s)
Lubiprostone Capsules 8 mcg oral capsules label showing a 60 capsule count. The packaging indicates the product is Rx only and instructs to swallow whole without breaking or chewing. It is manufactured for Northstar Rx LLC by Ascent Pharmaceuticals, Inc. The label includes storage instructions and a barcode.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of lubiprostone illustrating its molecular framework with oxygen, hydrogen, fluorine atoms, and carbon chains as part of the active pharmaceutical ingredient.*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
A table showing adverse reactions in clinical trials of adults with chronic idiopathic constipation (CIC) comparing placebo and Lubiprostone 24 mcg capsules taken twice daily. The table lists various adverse reactions such as nausea, diarrhea, headache, abdominal pain, and others, with their incidence percentages in both placebo and Lubiprostone groups.*
FDA Label Image

Table-1 (Table 1)

Table-1 (Table 1)
A dosage recommendation table for Lubiprostone capsules showing adult dosage regimens and dosage adjustments for hepatic impairment. It lists dosages for CIC and OIC as well as IBS-C conditions, detailing specific microgram amounts and frequency with notes on moderate and severe hepatic impairment adjustments.*
FDA Label Image

Table-3 (Table 3)

Table-3 (Table 3)
A data table presenting adverse reactions reported in clinical trials for adults with opioid-induced constipation (OIC). It compares the percentage of patients experiencing various adverse events such as nausea, diarrhea, abdominal pain, and others between placebo (N=632) and Lubiprostone Capsules 24 mcg taken twice daily (N=860).*
FDA Label Image

Table-4 (Table 4)

Table-4 (Table 4)
A data table comparing adverse reactions in clinical trials of adults with IBS-C for placebo versus lubiprostone capsules 8 mcg twice daily. The table lists the percentage of patients experiencing nausea, diarrhea, abdominal pain, and abdominal distension in each group.*
FDA Label Image

Table-5 (Table 5)

Table-5 (Table 5)
A data table titled 'Pharmacokinetic Parameters of the Metabolite M3 for Subjects with Normal or Impaired Liver Function following Dosing with Lubiprostone Capsules.' It shows mean values and standard deviations for AUC0-t and Cmax of metabolite M3 in subjects with normal liver function and Child-Pugh Class B and C liver impairment, including percentage changes compared to normal subjects.*
FDA Label Image

Table-6 (Table 6)

Table-6 (Table 6)
A data table titled "Adult Spontaneous Bowel Movement Frequency Rates (Efficacy Studies)" presenting mean, standard deviation, and median values for baseline through week 4 in two studies comparing placebo and Lubiprostone Capsules 24 mcg twice daily. The table includes week 1 and week 4 changes from baseline, showing the effect of treatment on spontaneous bowel movement frequency rates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.